Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib ...
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage ...
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2Planned workforce ...